ABBVIE, INC. for ABBVIE INC.
What was lobbied
5 issue areas, each in the filer's own words, with who lobbied on it and where.
Copyright/Patent/Trademark CPT
H.R. 2891, Preserve Access to Affordable Generics and Biosimilars Act H.R. 2873, Affordable Prescriptions for Patients Through Promoting Competition Act of 2021 H.R. 2883, Stop Stalling Access to Affordable Medications H.R. 2884, Affordable Prescriptions for Patients Through Improvements to Patent Litigation Act S. 2774, Pride in Patent Ownership Act S. 2891, Restoring the America Invents Act Patent litigation reform issues and issues related to post-grant proceedings at the USPTO Value of intellectual property
| Lobbyist | Covered position, as disclosed |
|---|---|
| DORCAS ADEKUNLE | — |
| DANIEL BACHNER | — |
| CRYSTAL RILEY | — |
| STEPHEN SCANGO | — |
Health Issues HCR
H.R. 5260, Reduced Costs and Continued Cures Act H.R. 5801, Help Ensure Lower Patient Copays Act S. 2164, Lower Costs, More Cures Act of 2021 Drug cost and pricing policy issues Patient affordability issues Policy proposals relating to clinical trial diversity Prescription Drug User Fee Act (PDUFA) reauthorization Issues related to the 340B program Administration plans to combat cancer and address other public health needs
| Lobbyist | Covered position, as disclosed |
|---|---|
| DORCAS ADEKUNLE | — |
| DANIEL BACHNER | — |
| CRYSTAL RILEY | — |
| STEPHEN SCANGO | — |
Medicare/Medicaid MMM
Public Law 117-169 (formerly known as H.R. 5376, Inflation Reduction Act), Implementation regarding Medicare Part D drug negotiation program Policy Proposals related to Medicare Part D and patient cost-sharing Department of Health and Human Services (HHS) drug policy issues and regulatory policy issues
| Lobbyist | Covered position, as disclosed |
|---|---|
| DORCAS ADEKUNLE | — |
| DANIEL BACHNER | — |
| CRYSTAL RILEY | — |
| STEPHEN SCANGO | — |
Taxation/Internal Revenue Code TAX
Public Law 115-97 (formerly known as H.R. 1, Tax Cuts and Jobs Act), Implementation Policy proposals relating to economic activity in Puerto Rico International tax issues, including OECD digital taxation work program
| Lobbyist | Covered position, as disclosed |
|---|---|
| DORCAS ADEKUNLE | — |
| DANIEL BACHNER | — |
| CRYSTAL RILEY | — |
| STEPHEN SCANGO | — |
Budget/Appropriations BUD
H.R. 2617, Consolidated Appropriations Act, 2023 - provisions related to the Prescription Drug User Fee Act (PDUFA) and corporate taxes
| Lobbyist | Covered position, as disclosed |
|---|---|
| DORCAS ADEKUNLE | — |
| DANIEL BACHNER | — |
| CRYSTAL RILEY | — |
| STEPHEN SCANGO | — |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.